Podcast/Video Interviews by Stephen Ibaraki

A Chat with Ali Khademhosseini: CEO and Founding Director at the Terasaki Institute for Biomedical Innovation (TIBI) about biomedical innovation

This week, Stephen Ibaraki has an exclusive interview with Ali Khademhosseini.

Ali Khademhosseini is currently the CEO and Founding Director at the Terasaki Institute for Biomedical Innovation (TIBI)

Previously, he was a Professor of Bioengineering, Chemical Engineering and Radiology at the University of California-Los Angeles (UCLA). He joined UCLA as the Levi Knight Chair in November 2017 from Harvard University where he was Professor at Harvard Medical School (HMS) and faculty at the Harvard-MIT's Division of Health Sciences and Technology (HST), Brigham and Women's Hospital (BWH) and as well as associate faculty at the Wyss Institute for Biologically Inspired Engineering. At Harvard University, he directed the Biomaterials Innovation Research Center (BIRC) a leading initiative in making engineered biomedical materials. Dr. Khademhosseini has served as an Associate Editor for ACS Nano from 2013 to 2021. He also served as the Research Highlights editor for Lab on a Chip.

He is a fellow of the American Institute of Medical and Biological Engineering (AIMBE), Biomedical Engineering Society (BMES), Royal Society of Chemistry (RSC), Biomaterials Science and Engineering (FBSE), Materials Research Society (MRS), NANOSMAT Society, and American Association for the Advancement of Science (AAAS).

He is also the recipient of the Mustafa Prize and is a member of the International Academy of Medical and Biological Engineering, Royal Society of Canada, Canadian Academy of Engineering, and National Academy of Inventors.

He is an author on >700 peer-reviewed journal articles, editorials and review papers, >70 book chapters/edited books and >50 patents/patent applications. He has been cited >125,100 times and has an H-index of 181. He is recognized by Stanford in the Top 10 for his work.

He has made seminal contributions to modifying hydrogels and developing novel biomaterial solutions for addressing pressing problems in healthcare. He has founded 3 companies, Obsidio Medical which was recently acquired by Boston Scientific, Omeat and BioRAE. He received his Ph.D. in bioengineering from MIT (2005), and MASc (2001) and BASc (1999) degrees from University of Toronto both in chemical engineering.